| Name | Title | Contact Details |
|---|
Leading with purpose; Briotech is dedicated to change health, healing, and disinfection with our proven pure HOCl and create jobs & partnerships globally.
ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
DotLab is shaping the future of women`s healthcare technology by developing the first test for endometriosis, affecting 1 in 10 women worldwide.
Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The companys proprietary drug discovery platform targets mTORC1, which responds to and integrates the cells response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitors therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The companys founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson and Johnson Development Corporation, SR One and The Longevity Fund.